Kura Oncology Inc. (KUR)

Overview

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel medicines for the treatment of cancer. With a strategic approach to cancer therapy, Kura Oncology leverages a pipeline of small molecule product candidates aimed at distinct cancer targets. Founded in 2014, the company is pioneering advancements in oncology, seeking to address unmet medical needs within the cancer treatment landscape. Headquartered in San Diego, California, Kura Oncology stands at the forefront of cancer research, aiming to deliver innovative solutions to patients worldwide.

Products and Services

• Ziftomenib

  This product candidate is an orally bioavailable small molecule inhibitor specifically designed to disrupt the interaction between menin and KMT2A. Targeting genetically defined subsets of acute leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), ziftomenib represents a promising avenue for the treatment of these challenging cancers.

• Tipifarnib

  Tipifarnib is an oral farnesyl transferase inhibitor that has shown potential when used in combination with alpelisib for patients suffering from PIK3CA-dependent Head and Neck Squamous Cell Carcinoma (HNSCC). This innovative approach leverages the inhibition of farnesyl transferase to potentially overcome cancer cell growth and survival in specific patient populations.

• KO-2806

  Serving as another farnesyl transferase inhibitor in Kura Oncology's arsenal, KO-2806 is currently being developed for the treatment of solid tumors. By targeting the same enzyme pathway as tipifarnib but with different properties, KO-2806 embodies the company’s commitment to diversifying its approach to cancer treatment through precision medicine.

In addition to its proprietary products, Kura Oncology has embarked on a clinical collaboration with Novartis Pharma AG. This partnership is dedicated to evaluating the combination of tipifarnib and alpelisib in a specific patient demographic with head and neck squamous cell carcinoma, highlighting the company's ongoing efforts to explore synergistic effects between different cancer therapies.